Home   »   Collaboration

Photo courtesy of Paul Ranky

Telocyte and CNIO

Telocyte and CNIO will be collaborating to take Telomerase Therapy to FDA human trials.

Under the direction of  Dr. Maria Blasco, C.N.I.O. – The Spanish National Research Centre, has recently made advances in both animal research and delivery systems that has facilitated an opportunity to pursue unsurpassed clinical advances in the field of telomerase therapy.  Dr. Blasco   is an internationally recognized expert in the field of telomerase

Her major research achievements include:



1. Isolation of the core components of mouse telomerase and generation of the first knockout mouse for telomerase;


2. Generation of the first mouse with increased telomerase expression in adult tissues;


3. The finding that mammalian telomeres and subtelomeres have epigenetic marks characteristic of constitutive heterochromatin;


4. Discovery of telomeric RNAs, which are potent telomerase-inhibitors whose expression is altered in cancer;


5. Demonstration that telomerase activity and telomere length determine the regenerative capacity of adult stem cells;


6. Identification of the longest telomeres as a universal feature of adult stem cell niches;


7. The finding that telomerase overexpression in the context of cancer resistant-mice improves organismal fitness, produces a systemic delay in ageing and an extension in median life-span;


8. Discovery that telomeres rejuvenate after nuclear reprogramming;


9. Identification of the molecular mechanisms by which short telomeres/DNA damage limit nuclear reprogramming of defective cells;


10. Discovery that telomeric protein TRF1 can act as both a tumour suppressor and as a factor in ageing prevention;